New Guidelines Lower the Bar for Cholesterol Treatment, Advocate Earlier Intervention

Significant updates to clinical guidelines for managing dyslipidemia, or high cholesterol, were released on March 13, 2026, by the American College of Cardiology (ACC) and the American Heart Association (AHA). These guidelines emphasize earlier intervention, including lifestyle changes in childhood and potential pharmacotherapy for younger individuals at risk. The updated recommendations replace the 2018 guidelines on blood cholesterol management.

Key Changes and Recommendations

The 2026 ACC/AHA guideline provides a comprehensive approach to evaluating, managing, and monitoring individuals with dyslipidemias, encompassing high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a) (Lp[a]). Here are some of the key recommendations:

• Early Intervention: A major focus is on initiating healthy lifestyle changes early in life, starting in childhood.
• Pharmacotherapy Consideration: Earlier consideration of medication (pharmacotherapy) is recommended for young people with familial hypercholesterolemia (FH) and young adults with LDL cholesterol (LDL-C) levels of 160 mg/dL or higher, or a strong family history of premature atherosclerotic cardiovascular disease (ASCVD).
• PREVENT Equations: The guideline recommends using the newer PREVENT-ASCVD equations, rather than the older Pooled Cohort Equations, for assessing 10- and 30-year risk of ASCVD in adults aged 30 to 79 years. This will facilitate guide decisions about lipid-lowering therapy (LLT).
• LDL-C Goals: LDL-lowering therapy is now considered reasonable for primary prevention of ASCVD in adults with a borderline 10-year PREVENT-ASCVD risk estimate of 3% to less than 5%, and is recommended for those with an intermediate risk of 5% to less than 10%, following a discussion between the clinician and patient.

Who Should Be Screened?

The updated guidelines apply to a broad range of individuals, including those with:

• High blood cholesterol
• Hypertriglyceridemia (high triglycerides)
• Elevated lipoprotein(a) (Lp[a])

Implications for Patients and Healthcare Providers

These new guidelines signal a shift towards more proactive cholesterol management. By identifying and addressing risk factors earlier, healthcare providers can potentially prevent or delay the onset of cardiovascular disease. Patients are encouraged to discuss their individual risk factors and appropriate treatment options with their doctors.

Looking Ahead

The release of these updated guidelines represents a significant step forward in the fight against cardiovascular disease. Continued research and implementation of these recommendations will be crucial in improving heart health for individuals of all ages.